argenx NV ADR (ARGX)vsArtiva Biotherapeutics, Inc. Common Stock (ARTV)
ARGX
argenx NV ADR
$927.21
+3.63%
HEALTHCARE · Cap: $58.31B
ARTV
Artiva Biotherapeutics, Inc. Common Stock
$4.15
+0.48%
HEALTHCARE · Cap: $204.85M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ARTV
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.3%
Fair Value
$2552.01
Current Price
$927.21
$1624.80 discount
Intrinsic value data unavailable for ARTV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 172.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : ARTV
The strongest argument for ARTV centers on Price/Book, Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ARTV
The primary concerns for ARTV are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ARTV is a value play — different risk/reward profiles.
ARTV carries more volatility with a beta of 2.41 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 30/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Artiva Biotherapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a promising pipeline targeting both hematologic and solid tumors, the company is at the forefront of innovation in the dynamic field of immuno-oncology. Leveraging its commitment to scientific excellence and strategic collaborations, Artiva is strategically positioned to advance its clinical candidates, thereby significantly improving patient outcomes in the fight against cancer. As it progresses through crucial clinical trials, the company's innovative approach holds the potential to reshape cancer treatment paradigms.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?